Triamcinolone Acetonide .25 mg/g Cream — NDC 33342-327-15 (Billing 33342-0327-15)
This is a package of Triamcinolone Acetonide .25 mg/g Cream from Macleods Pharmaceuticals Limited, marketed since May 2018 and currently FDA-listed; retail pharmacies pay about $0.1198 per g (NADAC). It is the main listing for this product, which comes in 2 package sizes.
Other active recalls for Triamcinolone Acetonide (different manufacturers) — 1 · tap to view
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 007593
- GCN: 31231
- GPI-14 (Medi-Span): 90550085103705
- HICL (First Databank): 002891
- AHFS class code: 48:10.08.00
- RxCUI (RxNorm): 1014314
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 1, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
RxNorm drug class
This medicine belongs to the Corticosteroid class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
Triamcinolone topical is used to treat the itching, redness, dryness, crusting, scaling, inflammation, and discomfort of various skin conditions, including psoriasis (a skin disease in which red, scaly patches form on some areas of the body and eczema (a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes). It is also used as a dental paste to relieve the discomfort of mouth sores. Triamcinolone is in a class of medications called corticosteroids. It works by activating natural substances in the skin to reduce swelling, redness, and itching.
Read the full MedlinePlus article ↗- It depends on the product. Injections treat severe allergic conditions, joint inflammation, certain skin problems and eye inflammation. Creams and ointments calm itchy, inflamed sk...
- Injections are given by a healthcare professional. Ointment is applied as a thin film to the affected area two to three times daily. Nasal spray bottles need priming before first u...
- Possible effects include injection site pain, joint swelling, headache, muscle spasms, cough, sinusitis and bruising. People with diabetes may see higher blood sugar. Tell your doc...
- Call right away for signs of an allergic reaction, fever or infection, a very painful and swollen joint, vision changes, or mood changes. Also report black stools, severe stomach p...
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Triamcinolone Acetonide — tap one for details:
Triamcinolone Acetonide may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 1, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per g | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.120 | $1.80 / 15 g |
| Medicaid paysCMS SDUD · 12 mo | $0.2997 | $4.50 / 15 g |
| Medicare drug plans payPart D · Q2 2026 | $0.1230 | $1.85 / 15 g |
Where does this data come from?
- CMS NADAC weekly file · file of Sep 30, 2026
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · through Q1 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Marketing end | Status |
|---|---|---|---|---|---|---|
| 33342-0327-15 You're viewing this Main listing | 1 TUBE in 1 CARTON / 15 g in 1 TUBE | $0.1198 / g | $1.80 | 2018-05-19 | — | Active |
| 33342-0327-80 33342-327-80 | 1 TUBE in 1 CARTON / 80 g in 1 TUBE | $0.0532 / g | $4.26 | 2018-05-19 | — | Active |
Per g, this pack runs about 125% above the cheapest pack (NDC 33342-0327-80, $0.0532 vs $0.1198 NADAC).
In Medicaid, this is the most-dispensed pack of this product — about 79% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in this package?
What NDC number is used to bill for this package of Triamcinolone Acetonide .25 mg/g Cream?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Triamcinolone Acetonide .25 mg/g 45802-0063-05 | Padagis | 454 g | $0.035 | AT | Availability likely | save 71% |
| Triamcinolone Acetonide .25 mg/g 45802-0054-05 | Padagis | 454 g | $0.047 | AT | Availability likely | save 61% |
| Triamcinolone Acetonide .25 mg/g 00168-0005-80 | E. | 80 g | $0.074 | AT | Availability likely | save 38% |
| triamcinolone acetonide .25 mg/g 00168-0003-15 | E. | 1 tube | $0.120 | AT | Availability likely | — |
| Triamcinolone Acetonide .25 mg/g 00713-0226-15 | Cosette | 1 tube | $0.120 | AT | Discontinued | — |
| Triamcinolone Acetonide .25 mg/g 16714-0985-01 | NorthStar | 1 tube | $0.120 | AT | Availability likely | — |
| Triamcinolone Acetonide .25 mg/gthis 33342-0327-15 | Macleods | 1 tube | $0.120 | AT | Availability likely | — |
| Triamcinolone Acetonide .25 mg/g 67877-0317-15 | Ascend | 15 g | $0.120 | AT | Availability likely | — |
| Triamcinolone acetonide .25 mg/g 33342-0331-15 | Macleods | 1 tube | $0.239 | AT | Availability likely | +100% |
| Triamcinolone Acetonide .25 mg/g 00713-0229-15 | Cosette | 1 tube | $0.239 | AT | Availability likely | +100% |
| Triamcinolone acetonide .25 mg/g 16714-0267-01 | NorthStar | 1 tube | $0.239 | AT | Availability likely | +100% |
| Triderm .25 mg/g 00316-0165-15 | Crown | 1 tube | — | AT | FDA listed | — |
| triamcinolone acetonide .25 mg/g 50090-0293-01 | A-S | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 50090-2658-00 | A-S | 15 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 50090-3704-00 | A-S | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 63187-0214-80 | Proficient | 80 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 63629-8782-01 | Bryant | 15 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 63629-8784-01 | Bryant | 454 g | — | AT | FDA listed | — |
| Triamcinolone acetonide .25 mg/g 68071-2361-01 | NuCare | 15 g | — | AT | FDA listed | — |
| triamcinolone acetonide .25 mg/g 68788-8515-08 | Preferred | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 68788-8899-01 | Preferred | 15 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 71335-2870-01 | Bryant | 454 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 72162-1835-02 | Bryant | 454 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 72162-2334-02 | Bryant | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 76420-0347-15 | Asclemed | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 76420-0360-80 | Asclemed | 80 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 63629-8841-01 | Bryant | 80 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 72162-2335-02 | Bryant | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 50090-3802-00 | A-S | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 68788-4148-01 | Preferred | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 50090-0362-00 | A-S | 1 tube | — | AT | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Sep 3, 2026
- CMS NADAC weekly file · file of Sep 30, 2026
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Sep 3, 2026
What it looks like
Where does this data come from?
- FDA label on DailyMed · label index refreshed Oct 1, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII LKG8494WBH
Benzyl alcohol is a clear liquid used as a preservative and solvent in medicines. It helps prevent bacterial and fungal growth and dissolves other ingredients to create uniform liquid formulations.
-
UNII 936JST6JCN
Cetyl alcohol is a waxy, fatty substance derived from plant or animal sources. It acts as an emulsifier and thickener in medicines, helping blend oil and water components and giving products a smooth, creamy texture.
-
UNII PDC6A3C0OX
Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
-
UNII 8CRQ2TH63M
Isopropyl palmitate is an oily liquid derived from palm oil. It acts as an emollient and lubricant in medicines, helping soften the skin or improve how the product spreads and flows.
-
UNII 33X04XA5AT
Lactic acid is a naturally occurring organic acid derived from milk or plant sources. It lowers and maintains pH in formulations, helps preserve the product, and can enhance ingredient stability and absorption.
-
UNII 506T60A25R
Sorbitol is a natural sugar alcohol derived from glucose. It serves as a sweetener, humectant, and bulking agent in medications to improve taste and help maintain moisture in the product.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
7 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 1, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS & USAGE: Triamcinolone cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
⏱️ Dosage and Administration ▾
DOSAGE & ADMINISTRATION: Apply Triamcinolone Acetonide Cream 0.025% to the affected area two to four times daily. Rub in gently. Apply the 0.1% or the 0.5% Triamcinolone Acetonide Cream, as appropriate, to the affected area two to three times daily.
Rub in gently. Occlusive Dressing Technique Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Gently rub a small amount of cream into the lesion until it disappears.
Reapply the preparation leaving a thin coating on the lesion, cover with pliable nonporous film, and seal the edges. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication. The frequency of changing dressings is best determined on an individual basis.
It may be convenient to apply triamcinolone acetonide cream under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion). When utilizing the 12-hour occlusion regimen, additional cream should be applied, without occlusion, during the day. Reapplication is essential at each dressing change.
If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
⛔ Contraindications ▾
CONTRAINDICATIONS: Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS: The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.
🤰 Pregnancy ▾
Pregnancy: Teratogenic Effects Category C. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.
There are no adequate and well controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
🧒 Pediatric Use ▾
Pediatric Use: Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids.Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation.
Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.
🆘 Overdosage ▾
OVERDOSAGE: Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS ).
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids.
There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin.
Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (See DOSAGE AND ADMINISTRATION ).
Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.
Some of the topical corticosteroids and their metabolites are also excreted into the bile.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Triamcinolone Acetonide Cream USP, 0.025% 15 gram tubes NDC 33342-327-15 80 gram tubes NDC 33342-327-80 Triamcinolone Acetonide Cream USP, 0.1% 15 gram tubes NDC 33342-329-15 30 gram tubes NDC 33342-329-30 80 gram tubes NDC 33342-329-80 1 Lb jars NDC 33342-329-54 Triamcinolone Acetonide Cream USP, 0.5% 15 gram tubes NDC 33342-328-15 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Avoid excessive heat. PROTECT FROM FREEZING.
Manufactured for: Macleods Pharma USA, Inc. Princeton, NJ 08540 Manufacturer: Macleods Pharmaceuticals Limited At Oxalis Labs Baddi, Himachal Pradesh, INDIA To report SUSPECTED ADVERSE REACTIONS, contact Macleods Pharma USA, Inc.at 1-888-943-3210 or 1-855-926-3384 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Revised: July 2023
📋 Description ▾
DESCRIPTION: The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and anti-pruritic agents. The steroids in this class include triamcinolone acetonide. Triamcinolone Acetonide Cream USP contains Triamcinolone Acetonide [Pregna-1, 4-diene-3, 20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene) bis- (oxy)]-, (11β,16α)-], with the empirical formula C 24 H 31 FO 6 and molecular weight 434.50.
CAS 76-25-5. The structural formula is: Triamcinolone Acetonide Cream USP, 0.025% contains: 0.25 mg of Triamcinolone Acetonide, USP per gram in a base containing Emulsifying Wax, Cetyl Alcohol, Isopropyl Palmitate, Sorbitol Solution, Glycerin, Lactic Acid, Benzyl Alcohol and Purified Water. Triamcinolone Acetonide Cream USP, 0.1% contains: 1 mg of Triamcinolone Acetonide, USP per gram in a base containing Emulsifying Wax, Cetyl Alcohol, Isopropyl Palmitate, Sorbitol Solution, Glycerin, Lactic Acid, Benzyl Alcohol and Purified Water.
Triamcinolone Acetonide Cream USP, 0.5% contains: 5 mg of Triamcinolone Acetonide, USP per gram in a base containing Emulsifying Wax, Cetyl Alcohol, Isopropyl Palmitate, Sorbitol Solution, Glycerin, Lactic Acid, Benzyl Alcohol and Purified Water. structure
💬 Information for Patients ▾
Information for the Patient: Patients using topical corticosteroids should receive the following information and instructions. 1. This medication is to be used as directed by the physician.
It is for dermatologic use only. Avoid contact with the eyes. 2.
Patients should be advised not to use this medication for any disorder other than for which it was prescribed. 3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.
4. Patients should report any signs of local adverse reactions especially under occlusive dressing. 5.
Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.
⚠️ Precautions ▾
PRECAUTIONS: General: Systemic absorption of topical corticosteroids has produced reversible hypothalamic pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of any potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests, and for impairment of thermal homeostasis.
If HPA axis suppression or elevation of the body temperature occurs, an attempt should be made to withdraw the drug, to reduce the frequency of application, substitute a less potent steroid, or use a sequential approach when utilizing the occlusive technique. Recovery of HPA axis function and thermal homeostasis are generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.
Occasionally, a patient may develop a sensitivity reaction to a particular occlusive dressing material or adhesive and a substitute material may be necessary. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see PRECAUTIONS , Pediatric Use ). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.
In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled. These preparations are not for ophthalmic use.
Information for the Patient: Patients using topical corticosteroids should receive the following information and instructions. 1. This medication is to be used as directed by the physician.
It is for dermatologic use only. Avoid contact with the eyes. 2.
Patients should be advised not to use this medication for any disorder other than for which it was prescribed. 3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.
4. Patients should report any signs of local adverse reactions especially under occlusive dressing. 5.
Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings. Laboratory Tests: A urinary free cortisol test and ACTH stimulation test may be helpful in evaluating HPA axis suppression. Carcinogenesis,Mutagenesis, and Impairment of Fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.
Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results. Pregnancy: Teratogenic Effects Category C. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels.
The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. LABOR & DELIVERY Nursing Mothers: It is not known whether topical administration of corticosteroids could result in suf… [Excerpted — this section continues on DailyMed.]
🍼 Nursing Mothers ▾
Nursing Mothers: It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
Carcinogenesis,Mutagenesis, and Impairment of Fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.
📄 Package Label / Principal Display Panel ▾
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Rx only Triamcinolone Acetonide Cream, 0.025%, 15 grams tube NDC: 33342-327-15 Rx only Triamcinolone Acetonide Cream, 0.025%, 15 grams carton NDC: 33342-327-15 Rx only Triamcinolone Acetonide Cream, 0.025%, 80 grams tube NDC: 33342-327-80 Rx only Triamcinolone Acetonide Cream, 0.025%, 80 grams carton NDC: 33342-327-80 Rx only Triamcinolone Acetonide Cream, 0.1%, 15 grams tube NDC: 33342-329-15 Rx only Triamcinolone Acetonide Cream, 0.1%, 15 grams carton NDC: 33342-329-15 Rx only Triamcinolone Acetonide Cream, 0.1%, 30 grams tube NDC: 33342-329-30 Rx only Triamcinolone Acetonide Cream, 0.1%, 30 grams carton NDC: 33342-329-30 Rx only Triamcinolone Acetonide Cream, 0.1%, 80 grams tube NDC: 33342-329-80 Rx only Triamcinolone Acetonide Cream, 0.1%, 80 grams carton NDC: 33342-329-80 Rx only Triamcinolone Acetonide Cream, 0.1%, 454 grams jar NDC: 33342-329-54 Rx only Triamcinolone Acetonide Cream, 0.5%, 15 grams tube NDC: 33342-328-15 Rx only Triamcinolone Acetonide Cream, 0.5%, 15 grams carton NDC: 33342-328-15 505 505 505 505 505 505 505 505 505 505 505 505 505